h
PSC
reg
®
Home
Browse
All cell lines
All hiPSC lines
All hESC lines
Cell line providers
Research projects
Countries
Diseases
Publications
Clinical studies
Info
About hPSCreg
FAQ
Cell Registration
Glossary
Documents & Governance
Fact Sheets
Naming Tool
Publishing your line
Structures
Registration Summary
Certification
Organoids
API
Export Data
SPARQL Guide
Contact
News
Newsletter Subscription
Privacy Policy
Terms of Use
Imprint
Login
Log-in
Sign up
Forgot your password?
This website uses cookies to keep track of login sessions and for internal Matomo Statistics. See our
Privacy Policy
for details.
This website uses cookies,
learn more
x
CSCRMi001-A
Registration Summary
:
A
P
E
C
POGLUT1 D233E - II.5-1
The cell line is
not submitted
yet.
(only basic data is shown)
General
Cell Line
hPSCreg name
CSCRMi001-A
Cite as:
When citing this cell line, please use the hPSCreg name (see
Naming Tool
) and the corresponding Research Resource ID (RRID).
CSCRMi001-A (RRID:CVCL_QX93)
Alternative name(s)
POGLUT1 D233E - II.5-1
Cell line type
Human induced pluripotent stem cell (hiPSC)
Similar lines
No similar lines found.
Last update
14th April 2022
User feedback
show/hide
Written by
on
Delete
No feedback available yet.
Login
to share your feedback, experiences or results with the research community.
Provider
Generator
Center for Stem Cell and Regenerative Medicine (CSCRM) / University of Texas Health Science Center at Houston (UTHealth) (CSCRM)
External Databases
Cellosaurus
CVCL_QX93
Wikidata
Q54814567
General Information
Publications
Rehakova D.. Standardized hiPSCs culture – vitronectin coating for cGMP compliant protocol. . 2017-01-01.
Wu J et al. Generation of an induced pluripotent stem cell line (CSCRMi001-A) from a patient with a new type of limb-girdle muscular dystrophy (LGMD) due to a missense mutation in POGLUT1 (Rumi). Stem cell research. 2017 Oct;24:102-105.
Angelini C et al. Advances in imaging of brain abnormalities in neuromuscular disease. Therapeutic advances in neurological disorders. 2019;12:1756286419845567.
Min YL et al. CRISPR Correction of Duchenne Muscular Dystrophy. Annual review of medicine. 2019 Jan 27;70:239-255.
Rajaei S et al. Meeting Between Rumi and Shams in Notch Signaling; Implications for Pain Management: A Narrative Review. Anesthesiology and pain medicine. 2019 Feb;9(1):e85279.
Uniyal AP et al. An overview of designing and selection of sgRNAs for precise genome editing by the CRISPR-Cas9 system in plants. 3 Biotech. 2019 Jun;9(6):223.
Yang Y et al. PHACTR1 is associated with disease progression in Chinese Moyamoya disease. PeerJ. 2020;8:e8841.
Bruge C et al. Skeletal Muscle Cells Derived from Induced Pluripotent Stem Cells: A Platform for Limb Girdle Muscular Dystrophies. Biomedicines. 2022 Jun 16;10(6).
Vargas-Franco D et al. The Notch signaling pathway in skeletal muscle health and disease. Muscle & nerve. 2022 Nov;66(5):530-544.
Rossiaud Lucille et al. Pathological modeling of glycogen storage disease type III with CRISPR/Cas9 edited human pluripotent stem cells. Frontiers in Cell and Developmental Biology. 2023-05-11.
Ortiz-Vitali Jose L. et al. Disease modeling and gene correction of LGMDR21 iPSCs elucidates the role of POGLUT1 in skeletal muscle maintenance, regeneration, and the satellite cell niche. Molecular Therapy - Nucleic Acids. 2023-09-00.
hIPSC Derivation
General
Login to share your feedback, experiences or results with the research community.